Lifecore Biomedical, Inc. (LFCR) Stock

Lifecore Biomedical, Inc. (LFCR) is a Healthcare stock trading at $4.56 (as of 2026-08-21), with a market capitalization of $172.61M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lifecore Biomedical, Inc. and its subsidiaries operate an integrated contract development and manufacturing organization, producing pharmaceutical-grade sodium hyaluronate and aseptically formulated injectable products, including filled syringes and vials, and providing development and validation services for clinical and commercial supply. Its Curation Foods segment processes, markets, and sells olive oils, wine vinegars, and guacamole/avocado products under company brands and private labels.

Understand Lifecore Biomedical, Inc.: how it makes money

Lifecore Biomedical operates as a contract development and manufacturing organization, making pharmaceutical-grade sodium hyaluronate and related injectable syringes and vials, and also providing development and analytical services, and earns money through CDMO and related manufacturing and development revenues.

The profit engine is turning contracted client programs into delivered, on-time manufacturing and finished injectable products and services, with production execution quality (for example, On-Time In-Fold Delivery Rate) and capacity to support revenue-generating output.

Revenue by segment (latest quarter)
LifeCorp	$0.0B
Life Course	$0.0B

Business quality (Mixed): The core business description and operating execution metric (On-Time In-Fold Delivery Rate) are clear, but the dataset shows total revenue reported as 0.0B while segment revenue candidates are small values, so investors should treat segment totals and comparisons as approximate.

Bull case

Operational execution metric is strong: On-Time In-Fold Delivery Rate is 97%.
Active program and pipeline indicators: There are 33 Development Programs Under Contract, 29 Commercial Projects Manufactured, and 11 Late-Stage Programs.
Pipeline visibility through opportunities in discussion: Prospective Pipeline Opportunities in Discussion is 68, and New Opportunities Qualified and Advanced is 50.

Bear case

Profitability is currently negative at the operating level: Operating margin is -20.1% (gross margin is 19.2%).
Some revenue may come from related parties: Revenue From Related Parties is listed as 0.01B.
Reported revenue scale looks very small in this dataset: Total revenue is shown as 0.0B for the 2026-03-31 period, which limits how much can be concluded from absolute revenue numbers here.

Valuation — source: SEC EDGAR (first-party)
Price	$4.56
Market Cap	$172.61M
EV / EBITDA	35.1
Price / Sales	1.38
FCF Yield	2.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$75.52M
Net Margin	-23.8%
Revenue Growth (YoY)	-6.2%
EPS Growth (YoY)	216.7%
FCF Growth (YoY)	-185.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.31 (distress)
Piotroski F-Score	3/9 (weak)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	22NW, LP ($18.87M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ryan D. Lake
Employees	524
Country	US
IPO Date	1996-02-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.